MESOTHELIOMA CHEMOTHERAPY: COMPARISON OF CISPLATIN AND CARBOPLATIN
Selasa, 04 Oktober 2016
Add Comment
A mesothelioma article recently published in the scientific journal Lung Cancer to examine the benefits and costs of Cisplatin and pemetrexed combination with Carboplatin and Pemetrexed for mesothelioma chemotherapy.
Cisplatin and pemetrexed combination chemotherapy is one of the few options of chemotherapy that has proven quite successful for treating patients with malignant pleural mesothelioma / malignant pleural mesothelioma (MPM), but this combination can be very toxic to the body. There is no treatment and treatment for malignant mesothelioma cancer without undesirable side effects.
In the journal, the researcher noted that "there are two phases of the randomized study in phase III showing the benefits for mesothelioma prognosis with the use of antifolates such as raltitrexed or pemetrexed, when combined with cisplatin. The study has demonstrated the absolute increase in overall survival average of 2.6 and 2.8 months, compared with single treatment for cisplatin. This makes many institutions use Cisplatin and pemetrexed as standard palliative chemotherapy treatment for malignant pleural mesothelioma. "
Unfortunately, the combination of cisplatin and pemetrexed produce unwanted toxic effects and this led researchers to study other chemotherapy drugs to be combined with pemetrexed. The researchers said, "Recently, two phase II trials had evaluated the efficacy of Carboplatin and Pemetrexed in MPM. Both studies showed an overall response rate of 18.6 and 25%, with a survival rate of 12.7 and an average of 14 months. Following on from these results, we have conducted a retrospective analysis in patients with MPM were treated with Carboplatin and Pemetrexed in our institution. "
In an effort to find a combination of chemotherapy mesothelioma with little toxicity and side effects, the researchers investigated further by replacing cisplatin with carboplatin when paired with pemetrexed. By using a retrospective approach, researchers evaluated 49 cases of malignant pleural mesothelioma who were given a combination of Carboplatin and Pemetrexed and compare the results with the data administration of cisplatin combination chemotherapy with pemetrexed.
The level of disease control (known by the absence of signs of progressive mesothelioma via CT scan) of the patients was 69 percent, and the percentage of partial response and stable disease by 28 percent and 41 percent. Clinical improvement shown in figure 69 percent, the majority of patients reported an increase in profits after two cycles of chemotherapy. Toxicity was generally low and better than the toxicity of cisplatin with pemetrexed.
The average time of treatment failure was 4.6 months. The average overall survival in this study was 14 months, compared with cisplatin-pemetrexed for 12.1 months. The authors suggested, "In conclusion, our data show a combination of Carboplatin and Pemetrexed may be an option in the treatment of mesothelioma, particularly in patients who are having problems with the use of cisplatin."
0 Response to "MESOTHELIOMA CHEMOTHERAPY: COMPARISON OF CISPLATIN AND CARBOPLATIN"
Posting Komentar